AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Coppell Advisory Solutions LLC

Coppell Advisory Solutions LLC raised its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 75.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,230 shares of the company's stock after purchasing an additional 14,339 shares during the quarter. Coppell Advisory Solutions LLC's holdings in AstraZeneca were worth $2,179,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of AZN. MGO One Seven LLC boosted its holdings in AstraZeneca by 137.7% during the 4th quarter. MGO One Seven LLC now owns 37,937 shares of the company's stock valued at $2,486,000 after acquiring an additional 21,977 shares during the period. Diadema Partners LP acquired a new position in shares of AstraZeneca in the fourth quarter valued at approximately $1,966,000. Eversept Partners LP purchased a new stake in AstraZeneca during the 4th quarter worth approximately $6,726,000. SIH Partners LLLP acquired a new stake in AstraZeneca during the 4th quarter worth approximately $783,000. Finally, Fayez Sarofim & Co boosted its position in AstraZeneca by 5.8% in the 4th quarter. Fayez Sarofim & Co now owns 3,643,010 shares of the company's stock valued at $238,690,000 after buying an additional 198,977 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on AZN shares. Morgan Stanley started coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. Finally, UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of "Buy" and an average target price of $86.80.

AstraZeneca Stock Up 0.0 %

AZN stock traded up $0.02 during trading on Friday, hitting $69.57. 6,662,575 shares of the company's stock were exchanged, compared to its average volume of 5,181,905. The stock has a market capitalization of $215.75 billion, a price-to-earnings ratio of 30.78, a PEG ratio of 1.42 and a beta of 0.49. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $72.33 and a two-hundred day moving average price of $70.25.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were given a dividend of $1.03 per share. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. The ex-dividend date was Friday, February 21st. AstraZeneca's payout ratio is presently 91.15%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.